Elisabetta Abruzzese

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz et al. · Blood · 2018 · 583 citations · Full text

Medicine, Hematology, Oncology +11

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Clinical Cancer Research · 2006 · 512 citations · Full text

Medicine, Hematology, Oncology +15

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Carlo Gambacorti‐Passerini, Laura Antolini, François‐Xavier Mahon et al. · JNCI Journal of the National Cancer Institute · 2011 · 428 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +15

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab

Roberto Stasi, Nichola Cooper, Giovanni Del Poeta et al. · Blood · 2008 · 406 citations

Life Sciences, Hematology, Immunology +14